Pfizer to buy Allergan in US$160b deal to create No 1 drugmaker
Acquisition will be biggest this year; Pfizer chief will head combined company
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
New York
PFIZER Inc, the maker of Viagra and Lipitor, has struck a deal to buy Botox-maker Allergan plc in a transaction valued at about US$160 billion, creating the world's biggest drugmaker. New York-based Pfizer and Allergan, headquartered in Ireland, said on Monday that Pfizer would offer 11.3 of its own shares for each Allergan share.
Pfizer stockholders will receive one share of the combined company for each of their Pfizer shares. The offer values Allergan's shares at US$363.63 each, compared with the stock's close of US$312.46 on Friday.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Why where you park your joint venture matters: Lessons from a US$689 million shareholder dispute
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Singaporeans can now buy record amount of yen per Singdollar
